Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

4-HO-MET

From Wikipedia, the free encyclopedia
Chemical compound

Pharmaceutical compound
4-HO-MET
Clinical data
Other names4-OH-MET; 4-Hydroxy-N-methyl-N-ethyltryptamine; Metocin; Methylcybin
Routes of
administration
Oral[1]
Drug classNon-selectiveserotonin receptor agonist;Serotonin5-HT2A receptoragonist;Serotonergic psychedelic;Hallucinogen
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Onset of action≤30 minutes[1]
Duration of action4–6 hours[1][3]
Identifiers
  • 3-{2-[Ethyl(methyl)amino]ethyl}-1H-indol-4-ol
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC13H18N2O
Molar mass218.300 g·mol−1
3D model (JSmol)
  • CCN(C)CCc2c[nH]c1cccc(O)c12
  • InChI=1S/C13H18N2O/c1-3-15(2)8-7-10-9-14-11-5-4-6-12(16)13(10)11/h4-6,9,14,16H,3,7-8H2,1-2H3
  • Key:ORWQBKPSGDRPPA-UHFFFAOYSA-N

4-HO-MET, also known as4-hydroxy-N-methyl-N-ethyltryptamine, as well asmetocin ormethylcybin, is apsychedelic drug of thetryptamine and4-hydroxytryptamine families related topsilocin (4-HO-DMT).[1] It is takenorally.[1]

The drug acts as anon-selectiveserotonin receptor agonist, including of theserotonin5-HT2A receptor.[4][5][6][7] It is a closestructural analogue of psilocin (4-HO-DMT) and is the 4-hydroxyl analogue ofmethylethyltryptamine (MET).[1]

4-HO-MET was discovered byAlexander Shulgin in the 1970s.[8][9][1] It was first described in the literature byDavid Repke and colleagues in 1981.[10] The drug was encountered as a novelrecreational anddesigner drug by 2008.[11]

Use and effects

[edit]

In his bookTiHKAL (Tryptamines I Have Known and Loved),Alexander Shulgin lists the dose range of 4-HO-MET as 10 to 20 mgorally and itsduration as 4 to 6 hours.[1][12][3] However, a widerrecreational dose range of 2 to 45 mg or more orally, with a typical dose estimate of 15 mg, has also been reported.[13] The drug'sonset is said to be within 30 minutes.[1]

The effects of 4-HO-MET have been reported to includepupil dilation,euphoria,tingling sensations,perceptual changes,closed- andopen-eye visuals,synesthesia,time dilation, intensifiedperceptions,thoughts, andfeelings, and a general change in thought processes.[3][8][1] Other specific effects include alteration ofcolor and form, feelingsounds, and a wave-like experience with alternation between near-normal perception one moment and a "swirl of altered concept" the next moment.[1]

4-HO-MET is said to produce qualitative effects very similar to those ofpsilocin.[1][8][3] Shulgin has stated that he doubts it could be distinguished from psilocin in anyblindedclinical study.[1] However, the drug has also been described as being relatively or very light, more clear-headed and functional, and having lesshead space.[8] On the other hand, it is said to still produce strongpsychedelic visuals.[8] This profile of effects has been described as being analogous to the case of2C-B.[8]

In addition to its use on its own, 4-HO-MET, along with the related tryptamine psychedelic5-MeO-MiPT, is employed at low doses as a component of theMDMA-mimickingBorax combo.[14][15][16]

Interactions

[edit]
See also:Psychedelic drug § Interactions, andTrip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]
4-HO-MET activities
TargetAffinity (Ki, nM)
5-HT1A135–950 (Ki)
1,390 (EC50Tooltip half-maximal effective concentration)
90% (EmaxTooltip maximal efficacy)
5-HT1B331
5-HT1D197
5-HT1E161
5-HT1FND
5-HT2A4.0–177 (Ki)
18–97 (EC50)
54–95% (
Emax)
5-HT2B12 (Ki)
2.64–>20,000 (EC50)
44–71% (
Emax)
5-HT2C141–164 (Ki)
30–113 (EC50)
87–101% (
Emax)
5-HT3ND
5-HT4ND
5-HT5A304
5-HT670
5-HT760
α1A9,700
α1B,α1DND
α2A1,666–2,400
α2B,α2CIA
β1β3ND
β2ND
D125,000
D24,000
D36,700
D4,D5IA
H1483–820
H2IA
H3,H4ND
M1M3,M5ND
M2IA
I1ND
σ1,σ2IA
TAAR1Tooltip Trace amine-associated receptor 112,000 (Ki) (mouse)
3,100 (Ki) (rat)
2,500 (EC50) (mouse)
2,100 (
EC50) (rat)
>10,000 (
EC50) (human)
78% (
Emax) (mouse)
71% (
Emax) (rat)
SERTTooltip Serotonin transporter200–2,310 (Ki)
830–9,000 (IC50Tooltip half-maximal inhibitory concentration)
IA (EC50)
NETTooltip Norepinephrine transporter13,000 (Ki)
11,000 (IC50)
IA (EC50)
DATTooltip Dopamine transporter>26,000 (Ki)
>100,000 (IC50)
IA (EC50)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified.Refs:[4][5][6][7][17]

4-HO-MET binds to variousserotonin receptors and is known to act as anagonist of theserotonin5-HT2A,5-HT2B,5-HT2C, and5-HT1A receptors.[4][5][6][7] It is thought that thehallucinogenic effects ofserotonergic psychedelics like 4-HO-MET are mediated by serotonin 5-HT2A receptor activation.[18]

Pharmacokinetics

[edit]

Themetabolism of 4-HO-MET has been studied.[19]

Chemistry

[edit]

4-HO-MET, also known as 4-hydroxy-N-methyl-N-ethyltryptamine, is asubstituted tryptamine and4-hydroxytryptamine.[1] It is the 4-hydroxyderivative ofN-methyl-N-ethyltryptamine (MET) and is a closeanalogue ofpsilocin (4-hydroxy-N,N-dimethyltryptamine; 4-HO-DMT).[1]

Synthesis

[edit]

Thechemical synthesis of 4-HO-MET has been described.[1][10]

Analogues

[edit]

Analogues of 4-HO-MET includepsilocin (4-HO-DMT),4-HO-DET (ethocin),4-HO-MiPT (miprocin),4-HO-DPT (deprocin),4-HO-MPT (meprocin),4-HO-DALT (dalocin), and4-HO-MALT (malocin), among others.[1]4-AcO-MET (metacetin) is anesterprodrug of 4-HO-MET.[7]

History

[edit]

4-HO-MET was firstsynthesized and discovered byAlexander Shulgin in the 1970s.[8][9][1] It was first described in thescientific literature byDavid Repke and colleagues by 1981.[10] Subsequently, 4-HO-MET was described by Shulgin in his bookTiHKAL (Tryptamines I Have Known and Loved) in 1997.[1] It was encountered as a novelrecreational anddesigner drug inEurope by 2008.[11]

Society and culture

[edit]

Legal status

[edit]

Finland

[edit]

Scheduled in the "government decree on psychoactive substances banned from the consumer market".[20]

Germany

[edit]

4-HO-MET is ruled under the Neue-psychoaktive-Stoffe-Gesetz (NpSG) since July 18, 2019. Production and Import with intent to distribute is punishable. Possession is forbidden but not punishable, although ordering it in small quantities can still be seen as an intent to distribute it and be punished.[citation needed]

4-Propionoxy-N-methyl-N-ethyltryptamine (also referred to as 4-PrO-MET) is the ester prodrug of 4-HO-MET. Unlike many other tryptamine derivatives, it is currently not explicitly listed under the German Neue-psychoaktive-Stoffe-Gesetz (NpSG). This means that, while its use as a recreational substance is not legally permitted, the compound may be obtained and handled for legitimate research purposes, provided all other relevant legal requirements and safety regulations are observed.[citation needed]

Sweden

[edit]

The SwedishRiksdag added 4-HO-MET to Schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of May 1, 2012, published byMedical Products Agency in their regulation LVFS 2012:6.[21]

United Kingdom

[edit]

4-HO-MET is a class A drug in theUnited Kingdom, as a result of the tryptamine catch-all clause.[citation needed]

United States

[edit]

4-HO-MET is not scheduled at the federal level in theUnited States, but it is possible that it could be considered an analogue of psilocin, in which case purchase, sale, or possession could be prosecuted under theFederal Analogue Act.[22]

It is a schedule I substance in some states, such asSouth Dakota[23] andWest Virginia.[24]

See also

[edit]

References

[edit]
  1. ^abcdefghijklmnopqrsShulgin A,Shulgin A (September 1997).TiHKAL: The Continuation.Berkeley, California:Transform Press.ISBN 0-9630096-9-9.OCLC 38503252.https://www.erowid.org/library/books_online/tihkal/tihkal21.shtml
  2. ^"§ 54.1-3446. Schedule I."Virginia Law. Retrieved29 October 2023.
  3. ^abcdKjellgren A, Soussan C (2011). "Heaven and hell--a phenomenological study of recreational use of 4-HO-MET in Sweden".J Psychoactive Drugs.43 (3):211–219.doi:10.1080/02791072.2011.605699.PMID 22111404.
  4. ^abcRickli A, Moning OD, Hoener MC, Liechti ME (August 2016)."Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens"(PDF).European Neuropsychopharmacology.26 (8):1327–1337.doi:10.1016/j.euroneuro.2016.05.001.PMID 27216487.S2CID 6685927.
  5. ^abcGlatfelter GC, Naeem M, Pham DN, Golen JA, Chadeayne AR, Manke DR, et al. (April 2023)."Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice".ACS Pharmacol Transl Sci.6 (4):567–577.doi:10.1021/acsptsci.2c00222.PMC 10111620.PMID 37082754.
  6. ^abcKozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, Schmachtenberg JL, et al. (April 2023)."Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter".J Pharmacol Exp Ther.385 (1):62–75.doi:10.1124/jpet.122.001454.PMC 10029822.PMID 36669875.
  7. ^abcdKlein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, et al. (April 2021)."Investigation of the Structure-Activity Relationships of Psilocybin Analogues".ACS Pharmacol Transl Sci.4 (2):533–542.doi:10.1021/acsptsci.0c00176.PMC 8033608.PMID 33860183.
  8. ^abcdefgPalamar JJ, Acosta P (January 2020)."A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines".Human Psychopharmacology.35 (1) e2719.doi:10.1002/hup.2719.PMC 6995261.PMID 31909513.
  9. ^abZamberlan F, Sanz C, Martínez Vivot R, Pallavicini C, Erowid F, Erowid E, et al. (2018)."The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines".Front Integr Neurosci.12 54.doi:10.3389/fnint.2018.00054.PMC 6235949.PMID 30467466.4-OH-MET (4-Hydroxy-N-methyl-N-ethyltryptamine): substituted tryptamine and close analog of psilocin, first synthesized by A. Shulgin (Shulgin and Shulgin, 1997).
  10. ^abcRepke DB, Ferguson WJ, Bates DK (1981). "Psilocin analogs II. Synthesis of 3-[2-(dialkylamino)ethyl]-, 3-[2-( N -methyl- N -alkylamino)ethyl]-, and 3-[2-(cycloalkylamino)ethyl]indol-4-ols".Journal of Heterocyclic Chemistry.18 (1):175–179.doi:10.1002/jhet.5570180131.ISSN 0022-152X.
  11. ^ab"2015 Annual Reports on the implementation of Council Decision 2005/387/JHA".Europol. 2008. Retrieved30 March 2025.
  12. ^Shulgin AT (2003)."Basic Pharmacology and Effects". In Laing RR (ed.).Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137.ISBN 978-0-12-433951-4.
  13. ^Luethi D, Liechti ME (October 2018)."Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics".Int J Neuropsychopharmacol.21 (10):926–931.doi:10.1093/ijnp/pyy047.PMC 6165951.PMID 29850881.
  14. ^Baggott M (23 June 2023).Beyond Ecstasy: Progress in Developing and Understanding a Novel Class of Therapeutic Medicine. PS2023 [Psychedelic Science 2023, June 19–23, 2023, Denver, Colorado]. Denver, CO:Multidisciplinary Association for Psychedelic Studies.
  15. ^Hamilton Morris (28 November 2023)."POD 92: Understanding and Improving MDMA with Dr. Matthew Baggott".The Hamilton Morris Podcast (Podcast). Patreon. Retrieved30 November 2024.
  16. ^"Borax Combo (Synonyms: Blue Bliss)".naddi.org. National Association of Drug Diversion Investigators (NADDI). 14 December 2022. Retrieved21 November 2024.
  17. ^Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016)."In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1"(PDF).J Pharmacol Exp Ther.357 (1):134–144.doi:10.1124/jpet.115.229765.PMID 26791601. Archived fromthe original(PDF) on 9 May 2025.
  18. ^Nichols DE (April 2016)."Psychedelics"(PDF).Pharmacol Rev.68 (2):264–355.doi:10.1124/pr.115.011478.PMC 4813425.PMID 26841800.
  19. ^Bruni PS, Grafinger KE, Nussbaumer S, König S, Schürch S, Weinmann W (September 2018). "Study of the in vitro and in vivo metabolism of 4-HO-MET".Forensic Sci Int.290:103–110.doi:10.1016/j.forsciint.2018.06.037.PMID 30015274.
  20. ^"Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista" [Government Decree on psychoactive substances banned from the consumer market].Finlex (in Finnish). Finish Ministry of Justice.
  21. ^"Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika" [Regulations on changes in the Swedish Medicines Agency's regulations (LVFS 2011:10) on lists of narcotics](PDF) (in Swedish). Elanders Sverige AB. 2012-04-20. Archived fromthe original(PDF) on 2013-09-28. Retrieved2014-02-25.
  22. ^"21 U.S. Code § 841 - Prohibited acts A",LII / Legal Information Institute, retrieved2016-08-02
  23. ^"Chapter 34-20B Drugs and Substances Control".South Dakota Legislature. Retrieved2023-10-09.
  24. ^"Chapter 60A. Uniform Controlled Substances Act".West Dakota Legislature. Retrieved2023-10-09.

External links

[edit]
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
  • Bioisosteres:JRT
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Cyclized tryptamines
Isotryptamines
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=4-HO-MET&oldid=1323686201"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp